[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363586-105":59,"doc-detail-363586-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-value-of-combined-carbohydrate-antigen-19-9-and-duke-pancreatic-monoclonal-antigen-type-2-assessment-in-biliary-tract-cancer","Prognostic Value of Combined Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer","","Carbohydrate antigen 19-9 (CA19-9) is a recognized prognostic biomarker for biliary tract cancers (BTCs), but its clinical usefulness is limited when patients have Lewis antigen negativity or impaired fucosyltransferase 3 (FUT3) function, causing absent or reduced CA19-9 production. Duke pancreatic monoclonal antigen type 2 (DUPAN-2), a CA19-9 biosynthetic precursor, increases as a compensatory alternative. This study assesses whether combined preoperative CA19-9 and DUPAN-2 stratifies prognosis in resectable BTCs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-value-of-combined-carbohydrate-antigen-19-9-and-duke-pancreatic-monoclonal-antigen-type-2-assessment-in-biliary-tract-cancer/363586/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-value-of-combined-carbohydrate-antigen-19-9-and-duke-pancreatic-monoclonal-antigen-type-2-assessment-in-biliary-tract-cancer/363586.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CA19-9 limited as a prognostic biomarker in some BTC patients?","Question",{"text":112,"@type":113},"CA19-9 production can be absent or markedly reduced in patients with Lewis antigen negativity or incomplete FUT3 gene function, which reduces CA19-9’s clinical utility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped for biomarker assessment?",{"text":117,"@type":113},"Patients were classified into four preoperative groups based on CA19-9 and DUPAN-2 levels: normal CA19-9/normal DUPAN-2 (N/N), normal CA19-9/high DUPAN-2 (N/H), high CA19-9/normal DUPAN-2 (H/N), and high CA19-9/high DUPAN-2 (H/H).",{"name":119,"@type":110,"acceptedAnswer":120},"What biomarker combination predicted better outcomes?",{"text":121,"@type":113},"The N/N profile, with concurrent normal CA19-9 and DUPAN-2, independently predicted favorable overall survival and recurrence-free survival in multivariate analysis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363586,1790195084,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[https://doi.org/10.1245/s10434-026-19488-2](https://doi.org/10.1245/s10434-026-19488-2)  \nAnnals of Surgical Oncology (2026) 33:6041–6049  \nORIGINAL ARTICLE HEPATOBILIARY TUMORS  \nPrognostic Value of Combined Carbohydrate Antigen 19‑9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer  \nRyuta Shintakuya, MD1 · Kenichiro Uemura, MD1 · Tatsuaki Sumiyoshi, MD1 · Kenjiro Okada, MD1 · Takumi Harada, MD1 · ShoTazuma, MD1 · Yasutaka Ishii, MD2 · Shiro Oka, MD2 · Yoshiaki Murakami, MD3 · Shinya Takahashi, MD1  \nReceived: 9 January 2026 / Accepted: 10 March 2026 / Published online: 26 March 2026 © The Author(s) 2026  \nAbstract  \nBackground Carbohydrate antigen 19-9 (CA19-9) represents an established prognostic biomarker for biliary tract cancers (BTCs) . Clinical utility remains limited among patients with Lewis antigen negativity or incomplete fucosyltransferase 3 (FUT3) gene function, conditions associated with absent or reduced CA19-9 production. Duke pancreatic monoclonal antigen type 2 (DUPAN-2), a biosynthetic precursor of CA19-9, shows compensatory elevation under such conditions. This study evaluated the prognostic significance of the combined preoperative assessment of CA19-9 and DUPAN-2 among patients with resectable BTCs.  \nPatients and Methods Patients who underwent curative-intent surgery for BTCs between 2009 and 2022 were included. Eligible patients were classified into four groups according to preoperative biomarker levels: normal CA19-9/normal DUPAN-2 (N/N), normal CA19-9/high DUPAN-2 (N/H), high CA19-9/normal DUPAN-2 (H/N), and high CA19-9/high DUPAN-2 (H/H). Clinicopathological features, overall survival (OS), and recurrence-free survival (RFS) were compared. Multivariate analyses identified independent prognostic factors.  \nResults The cohort included 276 patients with BTCs who underwent curative resection, comprising 41 intrahepatic cholangiocarcinomas, 72 hilar cholangiocarcinomas, 57 distal cholangiocarcinomas, 53 gallbladder carcinomas, and 53 ampullary carcinomas. Age and tumor distribution showed no significant intergroup differences. The N/N group demonstrated significantly superior OS and RFS (P \u003C 0.001). Multivariate analysis identified the N/N profile as an independent favorable prognostic factor for OS and RFS (P \u003C 0.001) .  \nConclusions Concurrent normal CA19-9 and DUPAN-2 levels independently predicted favorable outcomes. Combined preoperative biomarker assessment may contribute to prognostic stratification of BTCs, including among patients with Lewis antigen negativity or impaired FUT3 function.  \nKeywords Biliary tract cancer · Carbohydrate antigen 19-9 · Duke pancreatic monoclonal antigen type 2  \n* Kenichiro Uemura, MD[umk@hiroshima-u.ac.jp](umk@hiroshima-u.ac.jp)  \n1 Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan  \n2 Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan  \n3 Digestive Disease Center, Hiroshima Memorial Hospital, Hiroshima, Japan  \nBiliary tract cancer (BTC) represents an aggressive, highrisk malignancy associated with poor prognosis, and surgical resection remains the only curative treatment associated with improved outcomes. Carbohydrate antigen 19-9 (CA19- 9) has been reported as a useful biomarker for prognostic evaluation in patients with BTC. 1 ,2 Among patients with fucosyltransferase 3 (FUT3) gene deficiency, defined as Lewis antigen negativity, or incomplete FUT3 gene function, CA19-9 production remains absent or markedly reduced, with reported reductions of up to 50% .3–7 Duke pancreatic monoclonal antigen type 2 (DUPAN-2), a precursor of CA19-9, undergoes conversion to CA19-9 through FUT3  \nactivity, followed by conversion of CA19-9 to sialyl-Lewis b through FUT2 . CA19-9 and DUPAN-2 exhibit a complementary relationship governed by FUT gene expression.4 Variants of the FUT3 gene include fully funct","cbCaiitrGNwsEANW","https://ap.wps.com/l/cbCaiitrGNwsEANW","pdf",746977,"English","# Background\n# Patients and Methods\n## Study design\n# Results\n# Conclusions","[{\"question\":\"Why is CA19-9 limited as a prognostic biomarker in some BTC patients?\",\"answer\":\"CA19-9 production can be absent or markedly reduced in patients with Lewis antigen negativity or incomplete FUT3 gene function, which reduces CA19-9’s clinical utility.\"},{\"question\":\"How were patients grouped for biomarker assessment?\",\"answer\":\"Patients were classified into four preoperative groups based on CA19-9 and DUPAN-2 levels: normal CA19-9/normal DUPAN-2 (N/N), normal CA19-9/high DUPAN-2 (N/H), high CA19-9/normal DUPAN-2 (H/N), and high CA19-9/high DUPAN-2 (H/H).\"},{\"question\":\"What biomarker combination predicted better outcomes?\",\"answer\":\"The N/N profile, with concurrent normal CA19-9 and DUPAN-2, independently predicted favorable overall survival and recurrence-free survival in multivariate analysis.\"}]","Prognostic Value of Combined Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer | PDF",1790151956,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e743edd59096f0a9208cf9218a2a76f2.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fc77c3ae42d3867a4b178238e0d79c1.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60d12ef07e1e2de2ffecbfa2b3fdca8d.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7eb96f3bf7d6fcf91befc49e75af725.webp",980,1301]